PolyNovo Limited (CALZF)

OTCMKTS · Delayed Price · Currency is USD
0.7956
0.00 (0.00%)
Jun 3, 2026, 4:00 PM EST
Market Cap527.93M -9.1%
Revenue (ttm)93.04M +20.7%
Net Income6.59M +67.3%
EPS0.01 +67.6%
Shares Out n/a
PE Ratio80.12
Forward PE52.29
Dividendn/a
Ex-Dividend Daten/a
Volume19,538
Open0.6000
Previous Close0.7956
Day's Range0.6000 - 0.7956
52-Week Range0.000001 - 1.0200
Beta1.28
Analystsn/a
Price Targetn/a
Earnings DateAug 25, 2026

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]

Sector Healthcare
Founded 1998
Employees 301
Stock Exchange OTCMKTS
Ticker Symbol CALZF

Financial Performance

In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.

Financial numbers in AUD Financial Statements

News

PolyNovo Earnings Call Transcript: H1 2026

Group sales rose 26% to AUD 68.2 million, led by strong U.S. and international growth, with Adjusted EBITDA up 82%. Manufacturing capacity expanded, clinical evidence base strengthened, and new markets targeted for further acceleration.

3 months ago - Transcripts

PolyNovo Quarterly report: H1 2026

PolyNovo has published its H1 2026 quarterly earnings report on February 19, 2026.

3 months ago - Filings

PolyNovo Slides: H1 2026

PolyNovo has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 19, 2026.

3 months ago - Filings

PolyNovo Slides: Investor Presentation

PolyNovo has posted slides in relation to its latest quarterly earnings report, which was published on November 17, 2025.

7 months ago - Filings

PolyNovo Transcript: AGM 2025

The meeting highlighted strong financial growth, global expansion, and robust product innovation, while addressing governance reforms and executive turnover. Shareholders raised concerns about board practices and share price volatility, with the company emphasizing ongoing governance improvements and strategic investments.

7 months ago - Transcripts

PolyNovo Earnings Call Transcript: H2 2025

Record sales and profit growth were driven by strong U.S. and international demand, new product launches, and operational leverage. Cash flow and margins improved, with continued expansion into new markets and indications expected to sustain momentum.

10 months ago - Transcripts

PolyNovo Annual report: H2 2025

PolyNovo has published its H2 2025 annual report on August 25, 2025.

10 months ago - Filings

PolyNovo Slides: H2 2025

PolyNovo has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.

10 months ago - Filings

PolyNovo Earnings Call Transcript: H2 2025

Strong global sales growth continues, led by the U.S. and supported by new product launches and international expansion. Cash position and profitability have improved, with no need for additional capital raising. Record monthly revenue and ongoing innovation support a positive outlook.

11 months ago - Transcripts

PolyNovo Earnings release: H2 2025

PolyNovo released its H2 2025 earnings on July 29, 2025, summarizing the period's financial results.

11 months ago - Filings